Dalia Amin

Citation:

Eldesoukey, N. A., R. A. A. Afify, D. G. Amin, and undefined, "CD200 expression in B-cell chronic lymphoproliferative disorders", Journal of investigative medicine, vol. 60, issue 1, pp. 56-61, 2012.

Abstract:

Background: Flowcytometry immunophenotyping (FCIP) is used for rapid, specific diagnosis of Bchronic lymphoproliferative disorders (BCLPDs). However; cases may deviate from the typical immunophenotype, therefore, there is a need for adding new marker(s) for differentiating BCLPDs. Lately, few researches highlighted CD200 expression in some BCLPDs. Our aim was to evaluate CD200 expression in different BCLPDs, and whether adding CD200 to BCLPDs-FCIP routine panels, could improve the ability of their differential diagnosis. Methods: We evaluated CD200 expression in 49 BCLPDs patients and 26 age and sex matched controls. FCIP first panel included CD5, CD19, sIg, CD23, CD22, CD79b and FMC7, for BCLPDs other than chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), CD11c, CD103, CD25 and CD10 were evaluated. Results: Using tricolor FCIP, CD200 showed high bright expression on CD5/19 positive clone in all BCLL patients (100%), with a mean of 94 ± 11%, in the 2 cases of HCL, CD200 was brightly expressed on 96 and 99% of cells. In all other BCLPDs including MCL, CD200 expression (on CD19/22 positive cells) was less than 20% with a mean of 10 ± 8% and a dim pattern. CD200 expression was significantly higher in CLL compared to NHL groups (P value < 0.001). Conclusion: Evaluating CD200 expression has a great impact on accurate BCLPDs diagnosis and could be added to the BCLPDs routine panels. The high expression of CD200 in B-CLL and HCL could open the option for targeted immune (Anti CD200) therapy.